Pfizer Hopes To Keep Sutent Successes Coming
Melinda Peer, 03.13.09, 03:50 AM EDT
Company’s drug to treat pancreatic cancer proves encouraging in a late-stage trial.
Pfizer Inc.
03/13/2009 4:01PM ET$14.54$0.523.71%
1 day3 mo1 yearAdvanced
At A GlanceChartNewsPeople
BATS Real-Time Market Data by XigniteResults from a late-stage Pfizer trial studying the effectiveness of Sutent in stemming the advancement of a rare pancreatic cancer were so encouraging that the company called it quits and extended the treatment to placebo-popping patients.
Under the recommendation of an independent data monitoring committee, Pfizer (nyse: PFE - news - people ) ended the study early because patients taking Sutent saw the disease’s progression halted for longer than those receiving a placebo and other supportive treatment. Current treatment options for the unusual cancer, with five to 10 annual cases per million people worldwide
Posted by on 03/14 at 02:11 AM
This marks the second time that Pfizer has halted a late-stage trial of Sutent because of positive results. The drug is currently approved to treat renal cell carcinoma, a type of kidney cancer, and as a backup treatment for rare tumors found in the gastrointestinal tract.
“We are delighted by these findings, which demonstrate that Sutent provides a benefit for patients with advanced well-differentiated pancreatic islet cell tumors--a rare cancer with limited treatment options,” said Mace Rothenberg, a senior vice president in Pfizer’s oncology division.
Posted by on 03/14 at 02:14 AM
Citigroup analyst John Boris said the news gives minimal upside to his current Sutent estimates, which are based on approval for Sutent’s use in treating larger tumor types. “Pfizer is examining multiple indications for Sutent, which would provide greater marketing opportunities than pancreatic islet tumors.” He said that these include the treatment of various stages of breast cancer, and late-stage programs for lung, colorectal and prostate cancers.
Boris estimates that Sutent sales will increase by 21.0% year over year, to $1.0 billion, in 2009. He maintains a “hold” rating on the company, citing declining sales volumes, a limited late-stage pipeline and expected pressure from generic drugs.
Hope this is some help I had to send 3 comments because it was to long. Your in my prayer Patrick hope works for you.
Posted by on 03/14 at 02:16 AM